Comparison of Evolocumab and Ezetimibe, both combined with Statin Therapy, for patients with recent Acute Coronary Syndrome: a cost-effectiveness analysis from …
X Xi, X Wang, W Xie, Y Jia, SZ Sanchez… - … Drugs and Therapy, 2023 - Springer
Purpose To assess the cost-effectiveness of evolocumab, a PCSK9 (proprotein convertase
subtilisin/kexin type 9) inhibitor, compared with ezetimibe, both added to background statin …
subtilisin/kexin type 9) inhibitor, compared with ezetimibe, both added to background statin …
Cost-effectiveness of evolocumab therapy for myocardial infarction: the Chinese healthcare perspective
Z Liang, Q Chen, F Yang, X Yan, X Zhang… - … drugs and therapy, 2021 - Springer
Purpose Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an
indispensable lipid-lowering treatment option, but their cost-effectiveness has been …
indispensable lipid-lowering treatment option, but their cost-effectiveness has been …
Cost-effectiveness of Evolocumab in Adult patients with atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective
W Xie, Y Song, X Qin, P Jin - Advances in Therapy, 2023 - Springer
Introduction To assess the cost-effectiveness of evolocumab with statins versus placebo
combined with statins in the treatment of adult patients with atherosclerotic cardiovascular …
combined with statins in the treatment of adult patients with atherosclerotic cardiovascular …
Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
Y Wan, J Liu, X Zhan, Y Zhang, R You - Cost Effectiveness and Resource …, 2023 - Springer
Abstract Background According to the Chinese guidelines for lipid management (2023),
evolocumab in combination with statins was recommended as secondary prevention of …
evolocumab in combination with statins was recommended as secondary prevention of …
Cost-effectiveness of PCSK9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
U Landmesser, P Lindgren, E Hagström… - … Heart Journal-Quality …, 2022 - escholarship.org
AimsTo assess the cost-effectiveness of proprotein convertase subtilisin/kexin type 9
inhibition with evolocumab added to standard-of-care lipid-lowering treatment [maximum …
inhibition with evolocumab added to standard-of-care lipid-lowering treatment [maximum …
Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome
Y Hao, Y Yang, Y Wang, J Li - International Heart Journal, 2022 - jstage.jst.go.jp
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors significantly reduce low-density
lipoprotein cholesterol (LDL-C) and improve the prognosis of patients with acute coronary …
lipoprotein cholesterol (LDL-C) and improve the prognosis of patients with acute coronary …
[HTML][HTML] Safety and effectiveness of evolocumab during acute and sub-acute phases of acute coronary syndrome (ACS): a systematic review and meta-analysis
AF Alzarroug, HK Al Gahtani, S Algahtani… - Cureus, 2023 - ncbi.nlm.nih.gov
Background: Coronary artery disease (CAD), manifested mainly as acute coronary
syndrome (ACS), continues to be a major cause of mortality globally and a significant …
syndrome (ACS), continues to be a major cause of mortality globally and a significant …
Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Y Zhang, Y Zhang, B Zhang, Z Chen, Y Wei, P Chen… - Clinical Therapeutics, 2022 - Elsevier
Purpose Evolocumab has been shown to improve cardiovascular outcomes in patients with
stable atherosclerotic disease. Whether this benefit persists in patients with acute coronary …
stable atherosclerotic disease. Whether this benefit persists in patients with acute coronary …
Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial
B Gencer, F Mach, SA Murphy, GM De Ferrari… - JAMA …, 2020 - jamanetwork.com
Importance The 2018 American Heart Association/American College of Cardiology
Multisociety Guideline on the Management of Blood Cholesterol identified patients with …
Multisociety Guideline on the Management of Blood Cholesterol identified patients with …
Cost-effectiveness analysis of evolocumab in adult patients with atherosclerotic cardiovascular disease in Canada
J Grégoire, S Champsi, M Jobin, L Martinez… - Advances in …, 2022 - Springer
Introduction To evaluate the cost-effectiveness of evolocumab when added to standard of
care lipid-lowering treatment (LLT) for patients with atherosclerotic cardiovascular disease …
care lipid-lowering treatment (LLT) for patients with atherosclerotic cardiovascular disease …
相关搜索
- cost effectiveness evolocumab in patients
- cost effectiveness healthcare perspective
- cost effectiveness myocardial infarction
- evolocumab in patients myocardial infarction
- evolocumab therapy healthcare perspective
- cost effectiveness statin therapy
- meta analysis effectiveness of evolocumab
- evolocumab in patients proprotein convertase
- evolocumab treatment chinese patients
- cost effectiveness proprotein convertase
- myocardial infarction healthcare perspective
- evolocumab in patients pcsk9 inhibition
- cost effectiveness pcsk9 inhibition
- early initiation chinese patients
- cost effectiveness patients with a history
- statin therapy healthcare perspective